# Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

- Source: PR Newswire M&A
- Published: 2026-11-07T15:03:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/johnson--johnson-announces-icotyde-icotrokinra-delivers-significant-improvement-in-psoriatic-arthritis-disease-activity-among-biologic-naive-patients-with-once-daily-targeted-oral-peptide-302932455.html
- Canonical: https://groundlevelnews.com/story/johnson-johnson-announces-icotyde-icotrokinra-delivers-significant-imp-e0888a/

Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._